Roche Holding AG (RHHBY)
30.91
+0.50
(+1.64%)
USD |
OTCM |
Apr 22, 16:00
Roche Price to Book Value: 5.649 for April 22, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| April 22, 2024 | 5.649 |
| April 19, 2024 | 5.557 |
| April 18, 2024 | 5.491 |
| April 17, 2024 | 5.497 |
| April 16, 2024 | 5.524 |
| April 15, 2024 | 5.588 |
| April 12, 2024 | 5.590 |
| April 11, 2024 | 5.658 |
| April 10, 2024 | 5.590 |
| April 09, 2024 | 5.603 |
| April 08, 2024 | 5.517 |
| April 05, 2024 | 5.526 |
| April 04, 2024 | 5.619 |
| April 03, 2024 | 5.720 |
| April 02, 2024 | 5.734 |
| April 01, 2024 | 5.839 |
| March 28, 2024 | 5.833 |
| March 27, 2024 | 5.722 |
| March 26, 2024 | 5.722 |
| March 25, 2024 | 5.718 |
| March 22, 2024 | 5.724 |
| March 21, 2024 | 5.724 |
| March 20, 2024 | 5.961 |
| March 19, 2024 | 5.870 |
| March 18, 2024 | 5.881 |
| Date | Value |
|---|---|
| March 15, 2024 | 5.965 |
| March 14, 2024 | 6.010 |
| March 13, 2024 | 6.254 |
| March 12, 2024 | 6.423 |
| March 11, 2024 | 6.325 |
| March 08, 2024 | 6.195 |
| March 07, 2024 | 6.171 |
| March 06, 2024 | 6.116 |
| March 05, 2024 | 6.058 |
| March 04, 2024 | 6.009 |
| March 01, 2024 | 6.045 |
| February 29, 2024 | 5.981 |
| February 28, 2024 | 6.018 |
| February 27, 2024 | 6.036 |
| February 26, 2024 | 5.943 |
| February 23, 2024 | 6.023 |
| February 22, 2024 | 5.937 |
| February 21, 2024 | 6.014 |
| February 20, 2024 | 5.983 |
| February 16, 2024 | 5.899 |
| February 15, 2024 | 5.866 |
| February 14, 2024 | 5.851 |
| February 13, 2024 | 5.872 |
| February 12, 2024 | 5.957 |
| February 09, 2024 | 5.904 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
5.491
Minimum
Apr 18 2024
12.77
Maximum
Apr 08 2022
8.511
Average
8.356
Median
Nov 05 2021
Price to Book Value Benchmarks
| Novartis AG | 4.166 |
| Pfizer Inc | 1.666 |
| ADC Therapeutics SA | -- |
| Novo Nordisk A/S | 35.32 |
| AC Immune SA | 1.246 |
Price to Book Value Related Metrics
| PE Ratio | 15.45 |
| PS Ratio | 2.936 |
| Price to Free Cash Flow | 15.51 |
| Price | 30.91 |
| Earnings Yield | 6.47% |
| Market Cap | 197.14B |
| Operating PE Ratio | 11.55 |
| Normalized PE Ratio | 15.27 |